We then tested OLN's efficacy on the viability of isogenic colorectal cancer cell lines, LIM1215 WT and R4, which are sensitive and resistant to Cetuximab (an anti-epidermal growth factor receptor therapy) respectively, with the resistant line R4 exhibiting higher GRP78 level (Fig. 5E). This evidence concerns the gene EGFR and colorectal cancer.